Teva Pharmaceuticals Ltd., announced it has launched CII, a generic version of the testosterone replacement therapy Axiron, a topical solution of the prescription medication used to treat adult males with low levels of testosterone due to injury, disease or defect. “We are pleased with the result in the district court, which has helped Teva add yet another product to our industry-leading generic portfolio, providing savings to our customers and to patients,” said Andy Boyer, Teva’s President and CEO, Global Generic Medicines, North America. Axiron is manufactured by Eli Lilly and Co., and has annual sales of about $247 million in ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.